For sale: Boston Chil­dren’s team touts a new CRISPR de­liv­ery sys­tem for triple-neg­a­tive breast can­cer — plus — af­ter test­ing it in mice and cells

A team of in­ves­ti­ga­tors at Boston Chil­dren’s has de­vel­oped a new de­liv­ery ve­hi­cle for CRISPR that amps up its abil­i­ty to elim­i­nate a key tar­get in triple-neg­a­tive breast can­cer — which they’ve demon­strat­ed in mice and tu­mor cells. And they have it up for auc­tion now in the hot on­col­o­gy field.

En­gi­neer­ing their way around the car­go lim­i­ta­tions and cell pen­e­tra­tion chal­lenges of cur­rent­ly used CRISPR de­liv­ery tech, the re­searchers used a new soft par­ti­cle de­liv­ery plat­form that they em­ployed to hone in on tu­mor cells us­ing an­ti­bod­ies to guide them to ICAM-1 mol­e­cules.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER